Piramal Pharma

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

19 Nov, 2025 | 04:48pm • Source: BSE

Please see enclosed Transcript of Conference Call on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended September 30, 2025

07 Nov, 2025 | 03:13pm • Source: BSE

Audio Recording of Conference Call on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th September, 2025

06 Nov, 2025 | 12:26pm • Source: BSE

Please see enclosed Investor Presentation - Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2025

05 Nov, 2025 | 09:05pm • Source: BSE

Please see enclosed Press Release - Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2025

05 Nov, 2025 | 09:02pm • Source: BSE

Please find enclosed Unaudited Financial Results (Standalone & Consolidated) for quarter ended September 30, 2025

05 Nov, 2025 | 09:00pm • Source: BSE

Please find enclosed outcome of Board Meeting held on November 5, 2025

05 Nov, 2025 | 08:55pm • Source: BSE

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

03 Nov, 2025 | 05:25pm • Source: BSE

Piramal Pharma Limited has informed the Exchange about Schedule of meet

24 Oct, 2025 | 12:35pm • Source: NSE

Pursuant to Regulation 30(6) of the SEBI Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analysts.

24 Oct, 2025 | 12:13pm • Source: BSE

Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2025 ,inter alia, to consider and...

24 Oct, 2025 | 12:08pm • Source: BSE

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Withdrawal of Credit Rating.

16 Oct, 2025 | 08:41pm • Source: BSE

Please find enclosed intimation on change in general email id of Company''s Registrar & Share Transfer Agent.

30 Sep, 2025 | 06:24pm • Source: BSE

Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information

09 Sep, 2025 | 06:52pm • Source: BSE

Intimation of Schedule of Analyst/ Institutional Investor Meeting under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

02 Sep, 2025 | 03:44pm • Source: BSE

Sustainability Report of Piramal Pharma Limited for the Financial Year 2024-25.

25 Aug, 2025 | 04:16pm • Source: BSE

Press Release- Piramal Pharma Solutions (''"PPS") and NewAmsterdam Pharma invest in dedicated suite to enhance Oral Solid Dosage capabilities at PPS'' Sellersville , Pennsylvania site

21 Aug, 2025 | 04:55pm • Source: BSE

Please refer attachment

20 Aug, 2025 | 09:07pm • Source: BSE

Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

20 Aug, 2025 | 06:03pm • Source: BSE

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Fire occurrence at a third-party warehouse utilized by Company

07 Aug, 2025 | 06:49pm • Source: BSE